原因:the expected launch of its SEQureDx Down syndrome test is delayed, due to the discovery by company officials of employee mishandling of R&D test data and results.
“
. . . . . .
The company said its board has formed a special committee of independent directors to oversee an independent investigation of the employees' activity related to the test data and results.
However, Sequenom also said its SEQureDx technology remained scientifically and technically sound. It said the company has not changed its plans to develop in parallel its RNA- and DNA-based methods for the Down Syndrome test and will endeavor to have a validated test in the fourth quarter of 2009.”